托克塞鲁丁是一种用于腹腔透析的新型透剂,具有保护性心血管作用
Valeria Kopytina1, Vanessa Marchant2,3, Raquel Rodrigues-Diez4
1Tissue and Organ Homeostasis Program, Cell-Cell Communication and Inflammation Unit, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
概括
作为一种潜在的透剂,Troxerutin对腹膜透析 (PD) 患者来说是有前途的. 与葡萄糖不同,托克塞鲁丁在临床前模型中减少了炎症和心血管损伤,为末期病治疗提供了更安全的替代方案.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心血管研究研究心血管研究
- 生物材料科学 生物材料科学
背景情况:
- 末期病 (ESRD) 患者依赖腹透析 (PD),但面临全身炎症和心血管问题.
- 在PD溶液 (PDS) 中的葡萄糖可以加剧这些并发症,从而产生对更安全的透剂的需求.
研究的目的:
- 评估托克塞鲁丁作为PD溶液中潜在的葡萄糖替代品.
- 为了评估托克塞鲁丁的透性,超过性和生物相容性.
- 在临床前模型中研究特洛克苏-PDS与葡萄糖-PDS的局部和全身效应.
主要方法:
- 使用人工膜和人体中皮细胞 (MCs) 的体外研究.
- 在5/6只经过切除的小鼠身上进行了体内研究,这些小鼠在60天内暴露于葡萄糖-PDS或素-PDS.
- 对组织损伤,促炎性标志物 (IL-6,VEGF-A) 和心脏损伤的评估.
主要成果:
- 托克塞鲁丁表现出与葡萄糖相比的透和超过能力,并增加了合体的好处.
- 葡萄糖-PDS,但不是troxerutin-PDS,降低了MC活力和增加了中体到中体的过渡.
- 与葡萄糖-PDS相比,长期的托克塞鲁丁-PDS治疗显著减少了腹膜加厚,炎症和心血管损伤.
结论:
- 托克塞鲁丁是一种较为生物相容的PD透剂,在临床前研究中没有显示任何不良影响.
- 在PD溶液中用troxerutin取代葡萄糖可以减轻ESRD患者的炎症和心血管并发症.
相关概念视频
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
379
Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
379
Peritoneal Dialysis I: Introduction and Procedure
2.2K
Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
2.2K
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
166
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
166
Drug Elimination by Renal Route: Tubular Secretion
3.2K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
3.2K
Hemodialysis II: Procedure and Complications
590
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
590
Renal Drug Excretion: Tubular Secretion
753
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
753


